Having trouble accessing articles? Reset your cache.

OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic.

The company plans to submit in six months an IND for its lead candidate --

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE